640 related articles for article (PubMed ID: 25142258)
1. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Tannir NM; Forero-Torres A; Ramchandren R; Pal SK; Ansell SM; Infante JR; de Vos S; Hamlin PA; Kim SK; Whiting NC; Gartner EM; Zhao B; Thompson JA
Invest New Drugs; 2014 Dec; 32(6):1246-57. PubMed ID: 25142258
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Phillips T; Barr PM; Park SI; Kolibaba K; Caimi PF; Chhabra S; Kingsley EC; Boyd T; Chen R; Carret AS; Gartner EM; Li H; Yu C; Smith DC
Invest New Drugs; 2019 Apr; 37(2):297-306. PubMed ID: 30132271
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
Pal SK; Forero-Torres A; Thompson JA; Morris JC; Chhabra S; Hoimes CJ; Vogelzang NJ; Boyd T; Bergerot PG; Adashek JJ; Li H; Yu X; Gartner EM; Carret AS; Smith DC
Cancer; 2019 Apr; 125(7):1124-1132. PubMed ID: 30624766
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M
Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628
[TBL] [Abstract][Full Text] [Related]
5. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
[TBL] [Abstract][Full Text] [Related]
7. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
8. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.
Massard C; Soria JC; Krauss J; Gordon M; Lockhart AC; Rasmussen E; Upreti VV; Patel S; Ngarmchamnanrith G; Henary H
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1057-1063. PubMed ID: 30915497
[TBL] [Abstract][Full Text] [Related]
9. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
Owonikoko TK; Hussain A; Stadler WM; Smith DC; Kluger H; Molina AM; Gulati P; Shah A; Ahlers CM; Cardarelli PM; Cohen LJ
Cancer Chemother Pharmacol; 2016 Jan; 77(1):155-62. PubMed ID: 26576779
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma.
McGregor BA; Gordon M; Flippot R; Agarwal N; George S; Quinn DI; Rogalski M; Hawthorne T; Keler T; Choueiri TK
Invest New Drugs; 2020 Dec; 38(6):1807-1814. PubMed ID: 32472319
[TBL] [Abstract][Full Text] [Related]
11. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
[TBL] [Abstract][Full Text] [Related]
12. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
Shapiro GI; Vaishampayan UN; LoRusso P; Barton J; Hua S; Reich SD; Shazer R; Taylor CT; Xuan D; Borghaei H
Invest New Drugs; 2017 Jun; 35(3):315-323. PubMed ID: 28070718
[TBL] [Abstract][Full Text] [Related]
13. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.
Moreno V; Sepulveda JM; Vieito M; Hernández-Guerrero T; Doger B; Saavedra O; Ferrero O; Sarmiento R; Arias M; De Alvaro J; Di Martino J; Zuraek M; Sanchez-Pérez T; Aronchik I; Filvaroff EH; Lamba M; Hanna B; Nikolova Z; Braña I
Ann Oncol; 2020 Jun; 31(6):780-788. PubMed ID: 32240793
[TBL] [Abstract][Full Text] [Related]
15. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Ribrag V; Dupuis J; Tilly H; Morschhauser F; Laine F; Houot R; Haioun C; Copie C; Varga A; Lambert J; Hatteville L; Ziti-Ljajic S; Caron A; Payrard S; Coiffier B
Clin Cancer Res; 2014 Jan; 20(1):213-20. PubMed ID: 24132920
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
[TBL] [Abstract][Full Text] [Related]
17. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
[No Abstract] [Full Text] [Related]
18. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
de Vos S; Forero-Torres A; Ansell SM; Kahl B; Cheson BD; Bartlett NL; Furman RR; Winter JN; Kaplan H; Timmerman J; Whiting NC; Drachman JG; Advani R
J Hematol Oncol; 2014 Jun; 7():44. PubMed ID: 24919462
[TBL] [Abstract][Full Text] [Related]
20. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]